 |
| |
| May-18-20 | Resumed |
BofA/Merrill |
Neutral |
$95 |
|
| May-12-20 | Upgrade |
JP Morgan |
Neutral → Overweight |
$105 |
|
| May-11-20 | Resumed |
Morgan Stanley |
Overweight |
$95 |
|
| Apr-20-20 | Upgrade |
RBC Capital Mkts |
Sector Perform → Outperform |
$79 → $93 |
|
| Mar-23-20 | Downgrade |
Societe Generale |
Buy → Hold |
|
|
| Feb-27-20 | Initiated |
Barclays |
Equal Weight |
$97 |
|
| Feb-06-20 | Initiated |
Mizuho |
Buy |
|
|
| Jan-07-20 | Initiated |
RBC Capital Mkts |
Sector Perform |
$86 |
|
| Dec-26-19 | Reiterated |
Cowen |
Outperform |
$90 → $98 |
|
| Sep-26-19 | Upgrade |
Citigroup |
Neutral → Buy |
$87 → $90 |
|
| Aug-20-19 | Upgrade |
Piper Jaffray |
Neutral → Overweight |
$80 |
|
| Jun-27-19 | Upgrade |
Wolfe Research |
Underperform → Peer Perform |
|
|
| Jun-26-19 | Upgrade |
SVB Leerink |
Mkt Perform → Outperform |
$88 |
|
| May-28-19 | Initiated |
Goldman |
Neutral |
|
|
| Apr-29-19 | Upgrade |
BMO Capital Markets |
Underperform → Market Perform |
|
|
| Mar-25-19 | Downgrade |
Argus |
Buy → Hold |
|
|
| Jan-23-19 | Initiated |
UBS |
Neutral |
$91 |
|
| Jan-03-19 | Downgrade |
BofA/Merrill |
Buy → Neutral |
|
|
| Dec-26-18 | Initiated |
Standpoint Research |
Buy |
|
|
| Oct-22-18 | Reiterated |
SunTrust |
Buy |
$157 → $135 |
|
|
|
| May-29-20 06:47PM | Gilead Continues to Build Cancer Franchise GuruFocus.com |
| 04:13PM | FDA Approves the First Oral Medication for the Management of Heavy Menstrual Bleeding Due to Uterine Fibroids in Pre-menopausal Women PR Newswire |
| May-28-20 09:10AM | Ironwood to Halt MD-7246 Development After Study Failure Zacks |
| 08:12AM | Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)? Zacks |
| May-27-20 05:48PM | Top 1st-Quarter Buys of Steven Cohen's Firm GuruFocus.com |
| 12:16PM | Point72 Asset Management Buys Micron Technology, Baxter GuruFocus.com |
| 10:50AM | Top Ranked Income Stocks to Buy for May 27th Zacks |
| 09:36AM | How Trading Your Own Retirement Can Fleece Your Financial Future - May 27, 2020 Zacks |
| 08:51AM | AbbVie, Ironwood to discontinue experimental IBS drug MarketWatch |
| 08:30AM | AbbVie Presents New Data at the European E-Congress of Rheumatology (EULAR) 2020 Showcasing Depth of its Rheumatology Portfolio PR Newswire |
| May-26-20 11:28AM | Hedge Funds Have Never Been This Bullish On AbbVie Inc (ABBV) Insider Monkey |
| 08:00AM | AbbVie Wrapped Its $63 Billion Allergan Buyout Is AbbVie Stock A Buy? Investor's Business Daily |
| May-25-20 11:45AM | This is Why AbbVie (ABBV) is a Great Dividend Stock Zacks |
| May-24-20 07:11AM | Better Buy: AbbVie vs. Merck Motley Fool |
| May-22-20 04:26PM | Coronavirus latest: Friday, May 22 Yahoo Finance Video |
| 01:36PM | Zacks Value Trader Highlights: AbbVie, B&G Foods, H&R Block, Microsoft and Apple Zacks |
| 12:10PM | Allergan Finance, LLC -- Moody's withdraws Allergan's ratings Moody's |
| 11:37AM | Better Buy: AbbVie vs. Eli Lilly Motley Fool |
| 10:41AM | Top Ranked Income Stocks to Buy for May 22nd Zacks |
| 08:50AM | Is AbbVie (ABBV) Stock a Solid Choice Right Now? Zacks |
| 01:05AM | Edited Transcript of ABBV earnings conference call or presentation 1-May-20 1:00pm GMT Thomson Reuters StreetEvents |
| May-21-20 03:48PM | Fmr. CDC Official: 'were not cutting any corners' on COVID-19 vaccine development Yahoo Finance Video |
| 09:56AM | Dr. Reddy's (RDY) Q4 Earnings Increase Y/Y, Revenues Beat Zacks |
| May-20-20 09:23AM | Here are the hot dogs that hedge funds have used to outperform this year MarketWatch |
| 08:59AM | AbbVie, Interactive, Inphi, Chegg and ServiceNow highlighted as Zacks Bull and Bear of the Day Zacks |
| 08:59AM | JPMorgan: 2 Stocks to Snap Up Now (And 1 to Avoid) TipRanks |
| 08:43AM | Top Ranked Value Stocks to Buy for May 20th Zacks |
| 07:35AM | 3 Value Stocks That Could Thrive in a Post-Pandemic World Zacks |
| 06:45AM | Bull of the Day: AbbVie (ABBV) Zacks |
| 06:42AM | J&J to Stop Sale of Talc-Based Baby Powder in North America Zacks |
| May-19-20 12:00PM | AbbVie (ABBV) Upgraded to Strong Buy: Here's What You Should Know Zacks |
| 11:30AM | Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year? Zacks |
| 07:51AM | New Strong Buy Stocks For May 19th Zacks |
| May-18-20 11:50AM | Is AbbVie (ABBV) a Great Value Stock Right Now? Zacks |
| 09:55AM | The Zacks Analyst Blog Highlights: JPMorgan Chase, AbbVie, Royal Dutch Shell, Gilead Sciences and Anthem Zacks |
| May-15-20 01:21PM | Top Stock Reports for JPMorgan, AbbVie & Royal Dutch Shell Zacks |
| 10:45AM | Pharma Stock Roundup: FDA Updates for LLY, AZN, MRK, BMY and SNY Zacks |
| 08:30AM | AbbVie Data at EHA Annual Congress Highlight Depth and Breadth of Transformative Blood Cancer Portfolio PR Newswire |
| May-14-20 08:00AM | AbbVie to Present at the UBS Virtual Healthcare Conference PR Newswire |
| 06:27AM | Is Now a Good Time To Buy Neurocrine Biosciences? Motley Fool |
| May-13-20 03:45PM | Dow Jones Slides 1,171 Points In 3 Days After Fed Chair Speech Sharpens Recession Fear Investor's Business Daily |
| 12:03PM | AbbVie's Potential Is 'Underappreciated,' Says Morgan Stanley Analyst Benzinga |
| 11:06AM | 2 Value Stocks That Will Make You Richer in May Motley Fool |
| 11:00AM | 3 Stocks That Could Help You Send Your Kids to College Motley Fool |
| 08:00AM | AbbVie Announces Final Results of Exchange Offers for Allergan Notes PR Newswire |
| 07:02AM | Is AbbVie a Buy Now That the Allergan Deal Is Done? Motley Fool |
| May-12-20 06:45PM | Wall Street Ends in the Red on Tuesday GuruFocus.com |
| 02:05PM | The Dow Cant Hang On and REITs Are Getting Crushed Barrons.com |
| 12:59PM | AbbVie Is a Buy as Allergan Deal Closes - A Look at the Charts TheStreet.com |
| 12:10PM | FORM 8.3 - ABBVIE INC - Amendment Business Wire |
| 11:04AM | AbbVie Stock Has 15% Upside With Merger Done, J.P. Morgan Analyst Says Barrons.com |
| 08:44AM | AbbVie Gets Favorable Analyst Reviews After Allergan Merger TheStreet.com |
| 06:23AM | AbbVie Inc. Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next Simply Wall St. |
| May-11-20 05:41PM | The Dow Slipped 109 Points Because Reopened Economies Arent Business as Usual Barrons.com |
| 12:59PM | AbbVie Stock Is Unsustainably Cheap After Allergan Acquisition Barrons.com |
| 10:43AM | The Reasons to Be in AbbVie: Valuation, Dividend Yield, Confidence in Guidance TheStreet.com |
| 08:05AM | Form 8.3 - AbbVie Inc. Business Wire |
| 06:38AM | Form 8.3 - ABBVIE INC Business Wire |
| May-10-20 07:55AM | AbbVie Stock: Love It or Leave It? Motley Fool |
| May-09-20 08:00AM | 3 Best Healthcare Stocks to Buy in May Motley Fool |
| May-08-20 04:54PM | AbbVie closes acquisition of Allergan MarketWatch |
| 04:15PM | AbbVie Completes Transformative Acquisition of Allergan PR Newswire |
| 11:45AM | Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice Zacks |
| 09:53AM | Signs That Your Trading Will Ruin Your Retirement - May 08, 2020 Zacks |
| 07:55AM | Form 8.3 - AbbVie Inc. Business Wire |
| 05:17AM | Form 8.3 - ABBVIE INC Business Wire |
| May-07-20 09:50PM | AbbVie Remains a Top Large-Cap Pick, Says Mizuho SmarterAnalyst |
| 08:21AM | Form 8.3 - AbbVie Inc. Business Wire |
| 05:43AM | Form 8.3 - Abbvie Inc Business Wire |
| May-06-20 07:23PM | DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600 PR Newswire |
| 02:53PM | 3 Dividend Stocks Perfect for Retirees Motley Fool |
| 11:13AM | The Charts of AbbVie Can Reach New Heights TheStreet.com |
| 10:51AM | Form 8.3 - Abbvie Inc - Amendment Business Wire |
| 10:23AM | AbbVie's Pending Acquisition of Allergan Earns FTC Approval Motley Fool |
| 08:42AM | The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle Benzinga |
| 08:35AM | US regulator clears AbbVies $63bn deal for Allergan Financial Times |
| 08:21AM | Form 8.3 - Abbvie Inc Business Wire |
| 08:07AM | Form 8.3 - AbbVie Inc. Business Wire |
| 03:38AM | AbbVie Scores US Antitrust Approval for $63B Allergan Deal SmarterAnalyst |
| May-05-20 10:34PM | AbbVie wins U.S. antitrust approval to buy Allergan Reuters |
| 08:43PM | AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes and Expects No Further Extensions of Expiration Date PR Newswire |
| 06:14PM | Abbvie's deal for Allergan clears U.S. antitrust hurdle MarketWatch |
| 05:51PM | AbbVie and Allergan Receive Clearance from U.S. Federal Trade Commission for AbbVie's Acquisition of Allergan PR Newswire |
| 08:08AM | Form 8.3 - AbbVie Inc. Business Wire |
| 07:01AM | AbbVie Receives Health Canada Approval for the Combination of VENCLEXTA® (venetoclax) with Obinutuzumab for Patients with Previously Untreated Chronic Lymphocytic Leukemia CNW Group |
| 06:59AM | Form 8.3 - ABBVIE INC Business Wire |
| May-04-20 02:29PM | Stock Market Today With Jim Cramer: Time to Sell Stocks? TheStreet.com |
| 07:57AM | Form 8.3 - ABBVIE PLC AMENDMENT Business Wire |
| 07:47AM | Form 8.3 - ABBVIE INC - Amendment Business Wire |
| 07:40AM | Form 8.3 - AbbVie Inc. Business Wire |
| 07:23AM | Form 8.3 - Abbvie Plc - Amendment Business Wire |
| 07:22AM | Drugmaker AbbVie Reiterates 2020 Guidance, Beats Quarterly Sales TipRanks |
| 05:43AM | Form 8.3 - ABBVIE INC Business Wire |
| 02:00AM | Form 8.3 - AbbVie Inc. Business Wire |
| May-03-20 09:21PM | Top Marijuana Stocks That Pay Dividends Investopedia |
| May-02-20 07:31AM | The 3 Most Important Things to Know About AbbVie's Q1 Update Motley Fool |
| May-01-20 05:55PM | AbbVie Beats 1st-Quarter Estimates, Keeps 2020 Guidance GuruFocus.com |
| 04:18PM | AbbVie's Humira Puts Up Strong Showing, But Allergan Questions Linger Investor's Business Daily |
| 02:30PM | AbbVie Inc (ABBV) Q1 2020 Earnings Call Transcript Motley Fool |
| 11:18AM | AbbVie Posts First-Quarter Earnings Beat on Strong Humira Sales TheStreet.com |
|
|
|
|
| AbbVie Inc., a research-based biopharmaceutical company, develops and markets pharmaceutical products in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a biologic therapy administered as an injection for autoimmune and intestinal diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty, and for the treatment of patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; and Janssen Biotech, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Stewart Jeffrey Ryan | SVP, US Commercial Operations | May 12 | Sale | 90.00 | 23,024 | 2,072,211 | 52,760 | May 12 05:44 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | May 05 | Sale | 85.00 | 19,445 | 1,652,825 | 0 | May 07 05:01 PM | | Durkin Brian L | VP, Controller | Mar 30 | Buy | 69.00 | 750 | 51,750 | 16,844 | Mar 20 04:56 PM | | Durkin Brian L | VP, Controller | Mar 20 | Buy | 67.50 | 800 | 54,000 | 16,094 | Mar 20 04:56 PM | | Durkin Brian L | VP, Controller | Mar 18 | Buy | 68.18 | 2,200 | 150,005 | 15,294 | Mar 20 04:56 PM | | RAPP EDWARD J | Director | Mar 03 | Buy | 87.87 | 2,875 | 252,617 | 2,875 | Mar 04 05:14 PM | | RICHMOND TIMOTHY J. | EVP, Chief HR Officer | Sep 27 | Sale | 75.02 | 15,515 | 1,163,873 | 0 | Oct 01 05:52 PM | | Schumacher Laura J | Vice Chairman | Sep 16 | Buy | 70.42 | 25,000 | 1,760,523 | 164,838 | Sep 18 04:25 PM | | Donoghoe Nicholas | SVP, Enterprise Innovation | Aug 29 | Buy | 66.19 | 7,525 | 498,057 | 13,090 | Aug 30 04:08 PM | | Stewart Jeffrey Ryan | SVP, US Commercial Operations | Aug 16 | Buy | 64.44 | 15,552 | 1,002,169 | 65,304 | Aug 20 04:16 PM | | AUSTIN ROXANNE S | Director | Aug 01 | Buy | 65.66 | 25,000 | 1,641,400 | 117,114 | Aug 02 05:02 PM | | AUSTIN ROXANNE S | Director | Jul 31 | Buy | 66.02 | 30,000 | 1,980,690 | 92,114 | Aug 02 05:02 PM | | AUSTIN ROXANNE S | Director | Jul 30 | Buy | 66.35 | 10,000 | 663,500 | 62,114 | Jul 31 04:46 PM | | Gosebruch Henry O | EVP, Chief Strategy Officer | Jul 29 | Buy | 67.28 | 30,000 | 2,018,385 | 75,763 | Jul 31 04:46 PM | | AUSTIN ROXANNE S | Director | Jun 26 | Buy | 67.50 | 11,500 | 776,250 | 52,114 | Jun 28 04:47 PM | | CHASE WILLIAM J | EVP, Finance & Administration | Jun 26 | Buy | 67.30 | 30,400 | 2,045,920 | 169,552 | Jun 28 04:47 PM | | RAPP EDWARD J | Director | Jun 26 | Buy | 67.30 | 7,500 | 504,750 | 30,662 | Jun 28 04:48 PM |
|
|
|
|
|
|
